We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Trasylol Continues To Cause Heartache For Bayer

Law360 (August 24, 2007, 12:00 AM EDT) -- Bayer AG may soon face regulatory scrutiny over Trasylol, with the U.S. Food and Drug Administration set to hear testimony from a group of outside experts as to whether the blood-clotting drug can cause kidney damage, heart failure and even death.

The FDA's Cardiovascular and Renal Drugs Advisory Committee and its Drug Safety and Risk Management Advisory Committee are scheduled to review Trasylol's safety at a meeting slated for Sept. 12, the agency said on Wednesday.

The committees will discuss clinical data for Trasylol, or aprotinin...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.